Related Experiment Videos
SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Metabolic Syndrome Among Patients with Type 2 Diabetes
Hadeeqah Zayaan Riaz Ahamed1, Sulthan Al Rashid2, Rajkapoor Balasubramanian3
1Kasr Al Ainy, Faculty of Medicine, Cairo University, Cairo, Egypt.
Introduction:
Metabolic syndrome (MetS) is a cardiometabolic disorder defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). It is closely linked with type 2 diabetes mellitus (T2DM). The main features of this condition include central obesity, high triglyceride levels, low high-density lipoprotein cholesterol (HDL-C), high blood pressure, and impaired fasting glucose. The bidirectional relationship between MetS and T2DM significantly increases the risk of cardiovascular and metabolic diseases. This review examines the role of sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide- 1 (GLP-1) receptor agonists in addressing the different issues associated with MetS. It also discusses their effect on blood sugar control and their benefits for heart and kidney health in people with T2DM.
Methods:
This study conducted a thorough review of clinical trials, meta-analyses, and guideline recommendations to gather evidence about how SGLT-2 inhibitors and GLP-1 receptor agonists work and their benefits in managing MetS in T2DM.
Results:
Both SGLT-2 inhibitors and GLP-1 receptor agonists have shown improvements in body weight, lipid levels, blood pressure control, and blood sugar management. Furthermore, there is strong evidence supporting their protective effects on heart and kidney health, underlining their importance as key treatments for high-risk patients with T2DM and MetS.
Discussion:
Several clinical studies have examined the role of SGLT-2 inhibitors and GLP-1 receptor agonists in addressing MetS, including central obesity, hypertriglyceridemia, low HDL levels, fasting hyperglycaemia, and hypertension.
Conclusion:
SGLT-2 inhibitors and GLP-1 receptor agonists form an effective strategy for managing MetS in the context of T2DM. Their broad effects on metabolism and well-known heart and kidney benefits make them vital parts of modern treatment for cardiometabolic conditions.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...